Ultragenyx Pharmaceutical Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Ultragenyx Pharmaceutical Inc. now
Current reporting with the operating signal separated from the noise.
Ultragenyx Pharmaceutical Inc UP0
The story matters when it changes Ultragenyx Pharmaceutical Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Ultragenyx Pharmaceutical Inc (RARE) Institutional Confidence
The story matters when it changes Ultragenyx Pharmaceutical Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Ultragenyx Pharmaceutical Inc (RARE) Risk Assessment: Volatility, Financial Risk & Investment Risk
The story matters when it changes Ultragenyx Pharmaceutical Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Ultragenyx Pharmaceutical Inc.: Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
The story matters when it changes Ultragenyx Pharmaceutical Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
The story matters when it changes Ultragenyx Pharmaceutical Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript
Investors are testing whether Ultragenyx Pharmaceutical Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.RARE Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. (RARE)
The development tests whether Ultragenyx Pharmaceutical Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript
Investors are testing whether Ultragenyx Pharmaceutical Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Ultragenyx Pharmaceutical Inc. Reports Statistically Significant Improvements in Cognitive Function for UX111 Treatment in Sanfilippo Syndrome Type A at WORLDSymposium™ 2025
The story matters when it changes Ultragenyx Pharmaceutical Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Ultragenyx Pharmaceutical Inc. Reports Preliminary 2024 Revenue Exceeding Guidance and Provides 2025 Financial Outlook
Investors are testing whether Ultragenyx Pharmaceutical Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest RARE filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Ultragenyx Pharmaceutical Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →